NARHEX LIFE SCIENCES LIMITED - Company Profile and Status at deListed

Shareholder links

COMPANY:

NLSwebsite NLSannouncements NLSnews
NLSemail

Website Rating: ratings

REGISTRY:

Link Market Services, Level 12, 680 George Street Sydney NSW 2000
Tel: 1300 554 474 Fax: 61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

c/- KR Corporate Compliance Pty Ltd, Level 2, 90 William St, Melbourne VIC 3000
Tel: 61 3 9605 5916 Fax: 61 3 9605 5928

Date first listed: 12/01/2005
Company Secretary: Mr Mourice Garbutt
Industry: Pharmaceuticals, Biotechnology & Life Sciences
Activities: Australian biotechnology company with a principal focus to develop and commercialize its anti-HIV protease inhibitor DG17
Directors and Executives:
   Anthony Say Director
   David Mandel Director
   Ian Reynolds Director

News and events

a Deed of Company Arrangement is executed	07/05/2010
David Ross and Richard Albarran of Hall Chadwick are appointed as administrators of the company - this does not augur well for shareholders	09/02/2010
releases quarterly report	01/02/2010
the Board of Directors advises that Dr Michael Cohen, the Company's Executive Chairman and Acting Managing Director, passed away suddenly overnight	19/11/2009
at the AGM of the shareholders of NLS held today in Melbourne, shareholders passed each of Resolutions no. 1 - 7 as set out in the Notice of Meeting dated 4 September 2009	16/10/2009
the AGM is to be held at 11:00am Friday 16 October 2009 at the offices of Lander & Rogers, Level 12, 600 Bourke Street, Melbourne Vic 3000	17/09/2009
releases Half Yearly Report and Accounts to December 2007 and Financial and Annual Report June 2008	16/07/2009
company responds to an ASX Query re Appendix 4C	21/11/2008
releases Quarterly report for entities admitted on the basis of commitments	31/10/2008
main items in the quarterly cash flow to June 2008 are R&D expense of $103k, an R&D refund of $193k and $114k cash remaining	31/07/2008
the company explains the reasons for its suspension from quotation and provides an update for shareholders	21/07/2008
releases its quarterly cash report to 31 March 2008 showing a deficit at operating level for the quarter of $214k and $12k balance remaining	30/04/2008
securities suspended from quotation following failure to lodge its half report for the period ended 31 December 2007	03/03/2008
suspension of trading is lifted following receipt of the Company’s Full Year Accounts for the period ended 30 June 2007	11/10/2007
securities suspended from quotation following failure to lodge financial statements for the period to 30 June 2007	01/10/2007

NARHEX LIFE SCIENCES LTD